Annamaria LANDOLFI

Dr. Annamaria LANDOLFI

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
Jacopo TroisiJacopo Troisi
Jacopo Troisi
Luca PierriLuca Pierri
Luca Pierri
ALAnnamaria LANDOLFI
Annamaria LANDOLFI
FMFrancesca Marciano
Francesca Marciano
ABAntonella Bisogno
Antonella Bisogno
Pietro VajroPietro Vajro
Pietro Vajro
To get insight into still elusive pathomechanisms of pediatric obesity and non-alcoholic fatty liver disease (NAFLD) we explored the interplay among GC-MS studied urinary metabolomic signature, gut liver axis (GLA) abnormalities, and food preferences (Kid-Med). Intestinal permeability (IP), small intestinal bacterial overgrowth (SIBO), and homeostatic model assessment-insulin resistance were investigated in forty children (mean age 9.8 years) categorized as normal weight (NW) or obese (body mass index 95th percentile, respectively) ± ultrasonographic bright liver and hypertransaminasemia (NAFLD). SIBO was increased in all obese children (p = 0.0022), IP preferentially in those with NAFLD (p = 0.0002). The partial least-square discriminant analysis of urinary metabolome correctly allocated children based on their obesity, NAFLD, visceral fat, pathological IP and SIBO. Compared to NW, obese children had (1) higher levels of glucose/1-methylhistidine, the latter more markedly in NAFLD patients; and (2) lower levels of xylitol, phenyl acetic acid and hydroquinone, the latter especially in children without NAFLD. The metabolic pathways of BCAA and/or their metabolites correlated with excess of visceral fat centimeters (leucine/oxo-valerate), and more deranged IP and SIBO (valine metabolites). Urinary metabolome analysis contributes to define a metabolic fingerprint of pediatric obesity and related NAFLD, by identifying metabolic pathways/metabolites reflecting typical obesity dietary habits and GLA perturbations.

15 October 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ALAnnamaria LANDOLFI
Annamaria LANDOLFI
Carlo RicciardiCarlo Ricciardi
Carlo Ricciardi
Leandro DonisiLeandro Donisi
Leandro Donisi
Giuseppe CesarelliGiuseppe Cesarelli
Giuseppe Cesarelli
Jacopo TroisiJacopo Troisi
Jacopo Troisi
MAMarianna Amboni
Marianna Amboni
Background: Parkinson’s disease is the second most frequent neurodegenerative disorder. Its diagnosis is challenging and mainly relies on clinical aspects. At present, no biomarker is available to obtain a diagnosis of certainty in vivo. Objective: The present review aims at describing machine learning algorithms as they have been variably applied to different aspects of Parkinson’s disease diagnosis and characterization. Methods: A systematic search was conducted on PubMed in December 2019, resulting in 230 publications obtained with the following search query: “Machine Learning” “AND” “Parkinson Disease”. Results: The obtained publications were divided into 6 categories, based on different application fields: “Gait Analysis - Motor Evaluation”, “Upper Limb Motor and Tremor Evaluation”, “Handwriting and typing evaluation”, “Speech and Phonation evaluation”, “Neuroimaging and Nuclear Medicine evaluation”, “Metabolomics application”, after excluding the papers of general topic. As a result, a total of 166 articles were analyzed after elimination of papers written in languages other than English or not directly related to the selected topics. Conclusion: Machine learning algorithms are computer-based statistical approaches that can be trained and are able to find common patterns from big amounts of data. The machine learning approaches can help clinicians in classifying patients according to several variables at the same time.

9 September 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Jacopo TroisiJacopo Troisi
Jacopo Troisi
GVGiorgia Venutolo
Giorgia Venutolo
CTConcetta Terracciano
Concetta Terracciano
MCMatteo Delli Carri
Matteo Delli Carri
Simone Di MiccoSimone Di Micco
Simone Di Micco
Alessio FasanoAlessio Fasano
Alessio Fasano
Background: The involvement of intercellular tight junctions and, in particular, the modulation of their competency by the zonulin pathway with a subsequent increase in epithelial and endothelial permeability, has been described in several chronic and acute inflammatory diseases. In this scenario, Larazotide, a zonulin antagonist, could be employed as a viable therapeutic strategy. Objective: The present review aims to describe recent research and current observations about zonulin involvement in several diseases and the use of its inhibitor Larazotide for their treatment. Methods: A systematic search was conducted on PubMed and Google Scholar, resulting in 209 publications obtained with the following search query: “Larazotide,” “Larazotide acetate,” “AT-1001,” “FZI/0” and “INN-202.” After careful examination, some publications were removed from consideration because they were either not in English or were not directly related to Larazotide. Results: The obtained publications were subdivided according to Larazotide’s mechanism of action and different diseases: celiac disease, type 1 diabetes, other autoimmune diseases, inflammatory bowel disease, Kawasaki disease, respiratory (infective and/or non-infective) diseases, and other. Conclusion: A substantial role of zonulin in many chronic and acute inflammatory diseases has been demonstrated in both in vivo and in vitro, indicating the possible efficacy of a Larazotide treatment. Moreover, new possible molecular targets for this molecule have also been demonstrated.

22 March 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Jacopo TroisiJacopo Troisi
Jacopo Troisi
ACAngelo Colucci
Angelo Colucci
Pierpaolo CavalloPierpaolo Cavallo
Pierpaolo Cavallo
SRSean Richards
Sean Richards
SSSteven Symes
Steven Symes
VAVincenzo Altieri
Vincenzo Altieri
Bladder cancer has a high incidence and is marked by high morbidity and mortality. Early diagnosis is still challenging. The objective of this study was to create a metabolomics-based profile of bladder cancer in order to provide a novel approach for disease screening and stratification. Moreover, the study characterized the metabolic changes associated with the disease. Serum metabolomic profiles were obtained from 149 bladder cancer patients and 81 healthy controls. Different ensemble machine learning models were built in order to: (1) differentiate cancer patients from controls; (2) stratify cancer patients according to grading; (3) stratify patients according to cancer muscle invasiveness. Ensemble machine learning models were able to discriminate well between cancer patients and controls, between high grade (G3) and low grade (G1-2) cancers and between different degrees of muscle invasivity; ensemble model accuracies were ≥80%. Relevant metabolites, selected using the partial least square discriminant analysis (PLS-DA) algorithm, were included in a metabolite-set enrichment analysis, showing perturbations primarily associated with cell glucose metabolism. The metabolomic approach may be useful as a non-invasive screening tool for bladder cancer. Furthermore, metabolic pathway analysis can increase understanding of cancer pathophysiology. Studies conducted on larger cohorts, and including blind trials, are needed to validate results.

19 November 2022 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
ALAnnamaria LANDOLFI
Annamaria LANDOLFI
MPMarina Picillo
Marina Picillo
MPMaria Teresa Pellecchia
Maria Teresa Pellecchia
JTJacopo Troisi
Jacopo Troisi
MAMarianna Amboni
Marianna Amboni
RERoberto Erro
Roberto Erro
Hyposmia is a common finding in Parkinson’s disease (PD) and is usually tested through the University of Pennsylvania Smell Identification Test (UPSIT). The aim of our study is to provide a briefer version of the Italian-adapted UPSIT test, able to discriminate between PD patients and healthy subjects (HS). By means of several univariate and multivariate (machine-learning-based) statistical approaches, we selected 8 items by which we trained a partial-least-square discriminant analysis (PLS-DA) and a decision tree (DT) model: class predictions of both models performed better with the 8-item version when compared to the 40-item version. An area under the receiver operating characteristic (AUC-ROC) curve built with the selected 8 odors showed the best performance (sensitivity 86.8%, specificity 82%) in predicting the PD condition at a cut-off point of ≤ 6. These performances were higher than those previously calculated for the 40-item UPSIT test (sensitivity 82% and specificity 88.2 % with a cut-off point of ≤ 21). Qualitatively, our selection contains one odor (i.e., apple) which is Italian-specific, supporting the need for cultural adaptation of smell testing; on the other hand, some of the selected best discriminating odors are in common with existing brief smell test versions validated on PD patients of other cultures, supporting the view that disease-specific odor patterns may exist and deserve a further evaluation.

23 November 2022 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ALAnnamaria LANDOLFI
Annamaria LANDOLFI
Claudia VinciguerraClaudia Vinciguerra
Claudia Vinciguerra
FDFrancesco Diana
Francesco Diana
FMFilomena Murano
Filomena Murano
MRMaria Claudia Russillo
Maria Claudia Russillo
GPGiuseppe Piscosquito
Giuseppe Piscosquito